Main competitors
Add to a list
1m. EPS revision 1m. Revenue rev. 4m. EPS revision 4m. Revenue rev. 1y. EPS revision 1y. Revenue rev. Divergence of Estimates Nbr of analysts
- 2
25
29
15
18
21
17
18
- - - 7
20
16
25
19
7
- - - -
10
21
4
13
Average 16
Weighted average by Cap. 22
Bio Therapeutic Drugs
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW